2024
Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regressionCerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study
Vedovati M, Shu L, Henninger N, Zubair A, Heldner M, Al Kasab S, Siegler J, Liebeskind D, Antonenko K, Yaghi S, Paciaroni M. Cerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study. Journal Of Thrombosis And Thrombolysis 2024, 57: 1008-1017. PMID: 38824485, PMCID: PMC11315801, DOI: 10.1007/s11239-024-02997-w.Peer-Reviewed Original ResearchCases of cerebral vein thrombosisVenous thromboembolismRisk of recurrent venous thromboembolismRadiological characteristics of patientsCerebral vein thrombosisRecurrent venous thromboembolismKaplan-Meier methodLog-rank testAbsence of headacheAll-cause-deathLogistic regression analysisCharacteristics of patientsCancer statusCohort studyPropensity score matchingConsecutive patientsAssociated with cancerRadiological characteristicsVein thrombosisStudy outcomesRecanalization rateOlder ageRisk factorsMultivariate analysisPatient management
2023
The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence
Muradashvili T, Restrepo V, Alameddine D, Soliman S, Feinn R, Chaar C, Lee A, Pine A. The Choice of Anticoagulant at First Recurrence Does Not Alter the Risk for the Second Recurrence. Blood 2023, 142: 5540. DOI: 10.1182/blood-2023-191084.Peer-Reviewed Original ResearchFirst VTE recurrenceDeep venous thrombosisFirst venous thromboembolismRecurrent VTE eventsVTE recurrenceVenous thromboembolismPulmonary embolismAnticoagulation regimenVTE eventsAnticoagulant regimenFirst recurrenceINR targetSecond recurrenceExact testFirst recurrent venous thromboembolismInferior vena cava atresiaLarge tertiary academic hospitalUnprovoked first venous thromboembolismMajor public health hazardDifferent anticoagulant agentsInterruption of anticoagulationCardiovascular risk factorsMay-Thurner syndromePatients 18 yearsRecurrent venous thromboembolismFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-Vitamin K Antagonist Oral AnticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized Controlled TrialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis
Shu L, Bakradze E, Omran SS, Giles J, Amar J, Henninger N, Elnazeir M, Liberman A, Moncrieffe K, Rotblat J, Sharma R, Cheng Y, Zubair AS, Simpkins A, Li G, Kung J, Perez D, Heldner MR, Scutelnic A, von Martial R, Siepen B, Rothstein A, Khazaal O, Do D, Al Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio HJ, Frontera JA, Kuohn L, Agarwal S, Stretz C, Kala N, ElJamal S, Chang A, Cutting S, Indraswari F, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad D, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Grory BM, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler J, Kamen S, Yu S, Guerrero CL, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind D, Furie K, Yaghi S. Predictors of Recurrent Venous Thrombosis After Cerebral Venous Thrombosis. Neurology 2022, 99: e2368-e2377. PMID: 36123126, PMCID: PMC9687409, DOI: 10.1212/wnl.0000000000201122.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisRecurrent venous thrombosisHistory of VTEVenous thrombosisVenous thromboembolismAntiphospholipid antibodiesBlack raceDiagnosis of CVTPositive antiphospholipid antibodiesRecurrent venous thrombosesAntiphospholipid antibody syndromeRecurrent venous thromboembolismCox regression analysisRisk of recurrenceMulticenter international studyAntibody syndromeOral anticoagulationVenous thrombosesConsecutive patientsRare causeMean ageTreatment strategiesThrombosisPatientsSecondary analysisPlacement and retrieval of bilateral iliac vein filters in patients with mega cava
Brahmandam A, Grubman S, Salem R, Davis KA, Tonnessen BH, Guzman RJ, Chaar C. Placement and retrieval of bilateral iliac vein filters in patients with mega cava. Journal Of Vascular Surgery Cases And Innovative Techniques 2022, 8: 610-615. PMID: 36248380, PMCID: PMC9556588, DOI: 10.1016/j.jvscit.2022.08.002.Peer-Reviewed Original ResearchVenous thromboembolismTherapeutic anticoagulationTemporary inferior vena cava filterInferior vena cava filterRecurrent venous thromboembolismBilateral iliac veinsInferior vena cavaVena cava filtersPulmonary embolismIliac veinVena cavaCava filtersPatientsSuccessful placementTemporary interruptionAnticoagulationContraindicationsCavaPresent reportThromboembolismEmbolismComplicationsPlacementDirect Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
Yaghi S, Saldanha IJ, Misquith C, Zaidat B, Shah A, Joudi K, Persaud B, Khalek F, Shu L, de Havenon A, Mistry EA, Bakradze E, Goldstein ED, Reagan J, Theodorou A, Palaiodimou L, Furie K, Field TS, Tsivgoulis G, Mac Grory B. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022, 53: 3014-3024. PMID: 35938419, DOI: 10.1161/strokeaha.122.039579.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVitamin K antagonistsVenous thrombosisK antagonistsSystematic reviewRelative riskObservational studyDirect Oral Anticoagulants Versus Vitamin K AntagonistsSafety of DOACsVitamin K antagonist treatmentRecurrent venous thromboembolismHigh-level evidenceLeast moderate riskVenous recanalizationOral anticoagulantsVenous thromboembolismMajor hemorrhageMore patientsAntagonist treatmentIntracranial hemorrhageCombination of keywordsComparable efficacyInclusion criteriaSafety outcomesEffect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism
Goldenberg N, Kittelson J, Abshire T, Bonaca M, Casella J, Dale R, Halperin J, Hamblin F, Kessler C, Manco-Johnson M, Sidonio R, Spyropoulos A, Steg P, Turpie A, Schulman S, French J, Fargo J, Crary S, Kumar R, Grace R, Trenor C, Wilson H, Hilliard L, Woods G, Patel K, Goldenberg N, Lowe E, Jaffray J, Young G, Rajpurkar M, Davila J, Mahajerin A, Cooper J, Gunawardena S, Zia A, Journeycake J, Carpenter S, Guerrera M, Diab Y, Tarango C, Gruppo R, Acharya S, Torres M, Shaffer L, Mignacca R, Haley K, Recht M, Thornburg C, Shah N, Mullen C, Mitchell D, Nakar C, Betensky M, Lawrence C, Takemoto C, Lo C, Scott-Emuakpor A, Kulkarni R, Borst A, O'Brien S, Corales-Medina F, Narang S, Kucine N, Wang M, Panigrahi A, McGowan K, Cramer S, Dandekar S, Xavier F, Knoll K, Verma A, Geddes A, Ahuja S, Hege K, Raybagkar D, Sharathkumar A, Srivath L, Khan O, Druzgal C, Bhatt M, Chan A, Brandao L, Massicotte P, van Ommen C, Male C, Monagle P, Nakano T, Mitchell W, Hiatt W, Weitz J. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA 2022, 327: 129-137. PMID: 35015038, PMCID: PMC8753509, DOI: 10.1001/jama.2021.23182.Peer-Reviewed Original ResearchConceptsClinically relevant bleeding eventsAnticoagulant therapy groupRecurrent venous thromboembolismSymptomatic recurrent venous thromboembolismDuration of anticoagulant therapyYears of ageAnticoagulant therapyBleeding eventsVenous thromboembolismTherapy groupAdverse eventsOptimal duration of anticoagulant therapyEnd pointsEffect of anticoagulant therapyProvoked venous thromboembolismPersistent antiphospholipid antibodiesPer-protocol populationPrimary end pointSafety end pointPrimary efficacy outcomePrimary safety outcomeVenous thromboembolism riskAbsolute risk reductionKaplan-Meier estimatesRandomized clinical trials
2021
Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism
Patel P, Patel P, Bhatt M, Braun C, Begum H, Nieuwlaat R, Khatib R, Martins C, Zhang Y, Etxeandia-Ikobaltzeta I, Varghese J, Alturkmani H, Bahaj W, Baig M, Kehar R, Mustafa A, Ponnapureddy R, Sethi A, Thomas M, Wooldridge D, Lim W, Bates S, Lang E, Le Gal G, Haramati L, Kline J, Righini M, Wiercioch W, Schünemann H, Mustafa R. Systematic review and meta-analysis of outcomes in patients with suspected pulmonary embolism. Blood Advances 2021, 5: 2237-2244. PMID: 33900385, PMCID: PMC8095140, DOI: 10.1182/bloodadvances.2020002398.Peer-Reviewed Original ResearchConceptsIncidence of VTENegative D-dimerPulmonary embolismVenous thromboembolismPretest probabilityMajor bleedingD-dimerNegative computed tomography scanRecurrent venous thromboembolismCochrane Central RegisterRecurrent pulmonary embolismLow pretest probabilityIntermediate pretest probabilityRelevant conference proceedingsComputed tomography scanHigh pretest probabilityPostthrombotic sequelaeCause mortalityCentral RegisterControlled TrialsIntracranial hemorrhagePrompt evaluationDiagnostic pathwayEligible studiesTomography scanEvaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).
Mesleh Shayeb A, Urman D, Dizman N, Meza L, Sivakumar A, Gan C, Dzimitrowicz H, Zhang T, Barata P, Bilen M, Gao X, Heng D, Pal S, Kaymakcalan M, McGregor B, Choueiri T, McKay R. Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). Journal Of Clinical Oncology 2021, 39: 291-291. DOI: 10.1200/jco.2021.39.6_suppl.291.Peer-Reviewed Original ResearchLow molecular weight heparinDirect oral anticoagulantsRenal cell carcinomaAdvanced renal cell carcinomaMajor bleeding eventsVenous thromboembolismBleeding eventsMajor bleedingSafety profileDifferent anticoagulantsSimilar bleeding riskRecurrent venous thromboembolismClear cell histologyRetrospective multicenter studyMolecular weight heparinCause of deathFisher's exact testLMWH useRCC outcomeBleeding riskMedian doseOral anticoagulantsPrimary endpointSecondary endpointsVTE events
2018
Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment
Juthani P, Ahmed D, Ahmed O, Bona R, Neparidze N, Lee A. Venous Thromboembolism (VTE) Education Preferences Amongst Physicians and Patients: A Qualitative Needs Assessment. Blood 2018, 132: 5810. DOI: 10.1182/blood-2018-99-119418.Peer-Reviewed Original ResearchVenous thromboembolismVTE patientsPrevention of VTESymptoms of VTERecurrent venous thromboembolismDeep venous thrombosisRandomized control trialLong-term managementOnline health educationMost patientsPulmonary embolismAdult patientsHospitalized patientsOncology providersVenous thrombosisHematology clinicCancer HospitalMedication adherenceOutpatient clinicTreatment optionsPatient interviewsPhysician interviewsMalignant hematologyPatient educationPreventable deathsAmerican Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism
Lim W, Le Gal G, Bates S, Righini M, Haramati L, Lang E, Kline J, Chasteen S, Snyder M, Patel P, Bhatt M, Patel P, Braun C, Begum H, Wiercioch W, Schünemann H, Mustafa R. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Advances 2018, 2: 3226-3256. PMID: 30482764, PMCID: PMC6258916, DOI: 10.1182/bloodadvances.2018024828.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDeep vein thrombosisRecurrent venous thromboembolismExtremity deep vein thrombosisVenous thromboembolismPulmonary embolismVTE riskUpper extremity deep vein thrombosisLower extremity deep vein thrombosisMcMaster University GRADE CentreDiagnostic strategiesHematology 2018 guidelinesHigh VTE riskLower VTE riskPretest probability assessmentTomography pulmonary angiographyVentilation-perfusion scanningClinical decision ruleEvidence-based guidelinesNew diagnostic modalitiesHealth care professionalsAmerican SocietyModern diagnostic strategiesVTE diagnosisVTE prevalenceRecommendations Assessment
2015
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings
Goldenberg N, Abshire T, Blatchford P, Fenton L, Halperin J, Hiatt W, Kessler C, Kittelson J, Manco‐Johnson M, Spyropoulos A, Steg P, Stence N, Turpie A, Schulman S, Punzalan R, Wang M, Jaffray J, Young G, Rajpurkar M, Carpenter S, Diab Y, Verdun N, Tarango C, Acharya S, Torres M, Kucine N, Mitchell B, Shah N, Thornburg C, Takemoto C, Kulkarni R, O'Brien S, Haley K, Recht M, Knoll C, Thornburg C, Geddis A, Ahuja S, Simpson M, Srivaths L, Journeycake J, Zia A. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. Journal Of Thrombosis And Haemostasis 2015, 13: 1597-1605. PMID: 26118944, PMCID: PMC4561031, DOI: 10.1111/jth.13038.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnticoagulantsChildChild, PreschoolColoradoDiagnostic ImagingEndpoint DeterminationFeasibility StudiesFemaleFloridaHemorrhageHumansInfantMaleObserver VariationPilot ProjectsQuality Assurance, Health CareRecurrenceReproducibility of ResultsResearch DesignSingle-Blind MethodTime FactorsVenous ThrombosisYoung AdultConceptsRandomized Controlled TrialsVenous thromboembolismSymptomatic recurrent venous thromboembolismControlled TrialsKids-DOTTDuration of anticoagulationClinically Relevant BleedingRecurrent venous thromboembolismPersistent antiphospholipid antibodiesDuration of therapyPatients aged <Pediatric venous thromboembolismMulticenter randomized controlled trialSafety event ratesAnticoagulant-relatedRelevant bleedingAntiphospholipid antibodiesPrimary efficacyPoor accrualSafety endpointsVenous thrombosisVenous occlusionInterobserver agreementRCT designObservational cohort
2013
Point-of-Care Focused Cardiac Ultrasound for Prediction of Pulmonary Embolism Adverse Outcomes
Taylor RA, Davis J, Liu R, Gupta V, Dziura J, Moore CL. Point-of-Care Focused Cardiac Ultrasound for Prediction of Pulmonary Embolism Adverse Outcomes. Journal Of Emergency Medicine 2013, 45: 392-399. PMID: 23827166, DOI: 10.1016/j.jemermed.2013.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overEchocardiographyEmergency Service, HospitalFemaleHemorrhageHospital MortalityHumansMaleMiddle AgedPoint-of-Care SystemsPredictive Value of TestsPrognosisPulmonary EmbolismRecurrenceRespiratory InsufficiencyRetrospective StudiesRisk FactorsShockVenous ThromboembolismVentricular Dysfunction, RightConceptsRight ventricular strainHospital adverse outcomesRetrospective chart reviewPulmonary embolismAdverse outcomesEmergency departmentChart reviewCardiac ultrasoundHighest positive likelihood ratioRecurrent venous thromboembolismLow negative likelihood ratioSignificant predictorsEmergency care practitionersFocused cardiac ultrasoundFOCUS examinationPositive likelihood ratioNegative likelihood ratioMajor bleedingLikelihood ratioRespiratory failureVenous thromboembolismTransthoracic echocardiographyHospital admissionIndependent predictorsVentricular strain
2005
Single Institution Experience with Inferior Vena Cava Filters.
Bhalla N, Bulgaru A, Church L, Kapur D, Lustberg H, Slater D, Dhami M. Single Institution Experience with Inferior Vena Cava Filters. Blood 2005, 106: 914. DOI: 10.1182/blood.v106.11.914.914.Peer-Reviewed Original ResearchDeep venous thrombosisRetrievable IVC filtersRecurrent deep venous thrombosisInferior vena cava filterSymptomatic pulmonary embolismPulmonary embolismPermanent IVC filtersIVC filtersVena cava filtersPermanent filtersClot burdenVenous thromboembolismCava filtersSymptomatic deep venous thrombosisTransient low-grade feverPoor pulmonary reserveRetrieval of filtersLow-grade feverRecurrent venous thromboembolismIncidence of complicationsIVC filter insertionLong-term anticoagulationSingle institution experienceAdverse clinical consequencesChest CT scan
2004
Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer
Tonnessen B, Money S. Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer. Perspectives In Vascular Surgery And Endovascular Therapy 2004, 16: 144-146. DOI: 10.1177/153100350401600217.Peer-Reviewed Original ResearchWeight heparin groupRecurrent venous thromboembolismRecurrent thromboembolismVenous thromboembolismWeight heparinAnticoagulation groupHeparin groupOpen-label clinical trialLowmolecular-weight heparinAcute venous thromboembolismOral anticoagulant therapyDeep vein thrombosisGroup of patientsMolecular weight heparinLower mortality rateOral anticoagulantsAnticoagulant therapyPulmonary embolismVein thrombosisCancer patientsClinical trialsEffective therapyThromboembolismMortality ratePatientsA Potentially Better Means of Preventing Recurrent Venous Thromboembolism Is on the Horizon
Weiss H, Trow T. A Potentially Better Means of Preventing Recurrent Venous Thromboembolism Is on the Horizon. Clinical Pulmonary Medicine 2004, 11: 120-121. DOI: 10.1097/01.cpm.0000117685.82901.2e.Peer-Reviewed Original ResearchVenous thromboembolismOral direct thrombin inhibitor ximelagatranRisk of recurrent thromboembolic eventsSecondary prevention of venous thromboembolismPreventing recurrent venous thromboembolismMonths of anticoagulant therapyPrevention of venous thromboembolismThrombin inhibitor ximelagatranRecurrent venous thromboembolismRecurrent thromboembolic eventsAnticoagulant therapyThromboembolic eventsSecondary preventionThromboembolismXimelagatran
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply